WO2010145644A3 - Zusammensetzung für den transport von orotsäure über die bluthirnschranke - Google Patents

Zusammensetzung für den transport von orotsäure über die bluthirnschranke Download PDF

Info

Publication number
WO2010145644A3
WO2010145644A3 PCT/DE2010/000676 DE2010000676W WO2010145644A3 WO 2010145644 A3 WO2010145644 A3 WO 2010145644A3 DE 2010000676 W DE2010000676 W DE 2010000676W WO 2010145644 A3 WO2010145644 A3 WO 2010145644A3
Authority
WO
WIPO (PCT)
Prior art keywords
orotic acid
transporting
blood
composition
brain barrier
Prior art date
Application number
PCT/DE2010/000676
Other languages
English (en)
French (fr)
Other versions
WO2010145644A2 (de
Inventor
Ulrich Werth
Joachim Ledwoch
Original Assignee
Werth Acupuncture Center S.L.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werth Acupuncture Center S.L.U. filed Critical Werth Acupuncture Center S.L.U.
Priority to EP10763117A priority Critical patent/EP2442808A2/de
Publication of WO2010145644A2 publication Critical patent/WO2010145644A2/de
Publication of WO2010145644A3 publication Critical patent/WO2010145644A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Die Erfindung betrifft eine Zusammensetzung für den Transport von Orotsäure über die Bluthirnschranke enthaltend eine Verbindung von Orotsäure mit einer Carriersubstanz, wobei die Verbindung von Orotsäure und der Carriersubstanz eine hohe Wasserlöslichkeit aufweist, sowie deren Verwendungen.
PCT/DE2010/000676 2009-06-15 2010-06-14 Zusammensetzung für den transport von orotsäure über die bluthirnschranke WO2010145644A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10763117A EP2442808A2 (de) 2009-06-15 2010-06-14 Zusammensetzung für den transport von orotsäure über die bluthirnschranke

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009025549.4 2009-06-15
DE102009025549A DE102009025549A1 (de) 2009-06-15 2009-06-15 Zusammensetzung für den Transport von Orotsäure über die Bluthirnschranke

Publications (2)

Publication Number Publication Date
WO2010145644A2 WO2010145644A2 (de) 2010-12-23
WO2010145644A3 true WO2010145644A3 (de) 2011-03-03

Family

ID=43069889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2010/000676 WO2010145644A2 (de) 2009-06-15 2010-06-14 Zusammensetzung für den transport von orotsäure über die bluthirnschranke

Country Status (3)

Country Link
EP (1) EP2442808A2 (de)
DE (1) DE102009025549A1 (de)
WO (1) WO2010145644A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981407A1 (de) * 2020-10-07 2022-04-13 WÖRWAG Pharma GmbH & Co.KG Biofaktoren zur behandlung und prophylaxe von demenz

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1947256A1 (de) * 1969-09-18 1971-03-25 Diamalt Ag Orotsaeurederivate mit verbesserter Wasserloeslichkeit und Verfahren zu ihrer Herstellung
DE2131946A1 (de) * 1971-06-26 1972-12-28 Storto Martin Dipl Chem Dr Salze der Orotsaeure mit Aminoalkoholen sowie Verfahren zu deren Herstellung und Anwendung
DD116036A1 (de) * 1973-12-27 1975-11-05
GB1477263A (en) * 1974-09-12 1977-06-22 Schnabel H Thiamindisulphidemono-orotate and process for its preparation
DE3112479A1 (de) * 1981-03-26 1982-11-25 Josef Dipl.-Chem. Dr.Rer.Nat. 1000 Berlin Klosa Nikotinsaeureamid-orotat
EP0820771A2 (de) * 1996-07-24 1998-01-28 WÖRWAG PHARMA GmbH Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
US20020049182A1 (en) * 1998-08-31 2002-04-25 Von Borstel Reid W. Compositions and methods for treatment of mitochondrial diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1947256A1 (de) * 1969-09-18 1971-03-25 Diamalt Ag Orotsaeurederivate mit verbesserter Wasserloeslichkeit und Verfahren zu ihrer Herstellung
DE2131946A1 (de) * 1971-06-26 1972-12-28 Storto Martin Dipl Chem Dr Salze der Orotsaeure mit Aminoalkoholen sowie Verfahren zu deren Herstellung und Anwendung
DD116036A1 (de) * 1973-12-27 1975-11-05
GB1477263A (en) * 1974-09-12 1977-06-22 Schnabel H Thiamindisulphidemono-orotate and process for its preparation
DE3112479A1 (de) * 1981-03-26 1982-11-25 Josef Dipl.-Chem. Dr.Rer.Nat. 1000 Berlin Klosa Nikotinsaeureamid-orotat
EP0820771A2 (de) * 1996-07-24 1998-01-28 WÖRWAG PHARMA GmbH Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
US20020049182A1 (en) * 1998-08-31 2002-04-25 Von Borstel Reid W. Compositions and methods for treatment of mitochondrial diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIHO H ET AL: "Neuroprotective effect of YM-39558 in focal cerebral ischemia in cats", NEUROPHARMACOLOGY, vol. 37, no. 2, 1 February 1998 (1998-02-01), Amsterdam, pages 159 - 168, XP002613507, ISSN: 0028-3908 *
CORNFORD E M ET AL: "Independent blood-brain barrier transport systems for nucleic acid precursors", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 394, no. 2, 25 June 1975 (1975-06-25), pages 211 - 219, XP025502613, ISSN: 0005-2736, [retrieved on 19750625], DOI: 10.1016/0005-2736(75)90259-X *
FURST W ET AL: "Prodrug approach of orotic acid using an absorption model", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 61, no. 1-2, 11 June 1990 (1990-06-11), pages 43 - 49, XP025557745, ISSN: 0378-5173, [retrieved on 19900611], DOI: 10.1016/0378-5173(90)90042-3 *

Also Published As

Publication number Publication date
WO2010145644A2 (de) 2010-12-23
EP2442808A2 (de) 2012-04-25
DE102009025549A1 (de) 2010-12-16

Similar Documents

Publication Publication Date Title
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
EA201270216A1 (ru) Фармацевтический состав
AU2011232516A8 (en) Chemical compounds
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
WO2011141110A3 (de) Photostabilisatoren
WO2012042371A3 (en) Pharmaceutical composition
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
ZA201200890B (en) 5,6-bicylic heteroaryl-containing urea compounds as kinase inhibitors
MY150778A (en) Fused heterocyclic compound
AP2011005982A0 (en) Asphalt-mineral compositions containing a cationicorganosilicon compound.
WO2010103362A3 (en) Process for the preparation of bosentan
WO2009083940A3 (en) Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts
WO2012079085A3 (en) Structure, synthesis, and applications for conjugated polyampholytes
WO2011015287A3 (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
EP1939688A4 (de) Zusammensetzung zur bildung eines antireflexfilms, umfassend ein reaktionsprodukt zwischen einer isocyanursäureverbindung und einer benzoesäureverbindung
AP2010005509A0 (en) Salts of HIV inhibitor compounds.
WO2009156724A3 (en) Pyrido-indole-carboxylic acid compounds
WO2010151045A3 (ko) 태양전지용 세정액 조성물
WO2010136104A3 (en) Anti-dandruff agents
WO2011089209A3 (de) Einraumverdampfer und deren verwendung bei der chemischen synthese
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10763117

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010763117

Country of ref document: EP